These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 15509187

  • 1. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.
    Jones MR, Baker BA, Mathew P.
    Clin Pharmacokinet; 2004; 43(13):943-50. PubMed ID: 15509187
    [Abstract] [Full Text] [Related]

  • 2. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD, Dane AL, Schneck DW, Warwick MJ.
    Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
    [Abstract] [Full Text] [Related]

  • 3. Effect of colesevelam on lovastatin pharmacokinetics.
    Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK.
    Ann Pharmacother; 2002 Mar; 36(3):392-7. PubMed ID: 11895049
    [Abstract] [Full Text] [Related]

  • 4. The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.
    Yun HY, Joo Lee E, Youn Chung S, Choi SO, Kee Kim H, Kwon JT, Kang W, Kwon KI.
    Clin Pharmacokinet; 2006 Mar; 45(4):425-32. PubMed ID: 16584288
    [Abstract] [Full Text] [Related]

  • 5. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR, Digiacinto J, Davis MW.
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [Abstract] [Full Text] [Related]

  • 6. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.
    Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A.
    Int J Clin Pharmacol Ther; 2006 Feb; 44(2):64-70. PubMed ID: 16502765
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia.
    McKenney J, Jones M, Abby S.
    Curr Med Res Opin; 2005 Sep; 21(9):1403-12. PubMed ID: 16197659
    [Abstract] [Full Text] [Related]

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C, Bujanover S, Kareht S, Rapoport AM.
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [Abstract] [Full Text] [Related]

  • 9. Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
    Gordon LA, Malati CY, Hadigan C, McLaughlin M, Alfaro RM, Calderón MM, Kovacs JA, Penzak SR.
    Pharmacotherapy; 2016 Jan; 36(1):49-56. PubMed ID: 26799348
    [Abstract] [Full Text] [Related]

  • 10. Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
    He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, Wight D.
    Diabetes Res Clin Pract; 2014 Jun; 104(3):401-9. PubMed ID: 24721587
    [Abstract] [Full Text] [Related]

  • 11. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
    He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, Wight D.
    J Clin Pharmacol; 2014 Jan; 54(1):61-9. PubMed ID: 24019110
    [Abstract] [Full Text] [Related]

  • 12. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.
    Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK.
    Cardiovasc Drugs Ther; 2000 Dec; 14(6):681-90. PubMed ID: 11300370
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers.
    Vlase L, Popa A, Muntean D, Leucuta SE.
    Arzneimittelforschung; 2010 Dec; 60(9):560-3. PubMed ID: 21117499
    [Abstract] [Full Text] [Related]

  • 14. Randomised crossover studies of the bioequivalence of two fenofibrate formulations after administration of a single oral dose in healthy volunteers.
    Sonet B, Vanderbist F, Streel B, Houin G.
    Arzneimittelforschung; 2002 Dec; 52(3):200-4. PubMed ID: 11963648
    [Abstract] [Full Text] [Related]

  • 15. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.
    Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, Wallin BA.
    J Clin Pharmacol; 2000 Mar; 40(3):316-23. PubMed ID: 10709162
    [Abstract] [Full Text] [Related]

  • 16. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R, Williams RX, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT.
    Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K, Lamson M, Salageanu J, Bramson C, Matschke K, Malhotra B.
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [Abstract] [Full Text] [Related]

  • 19. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia.
    Devaraj S, Autret B, Jialal I.
    Am J Cardiol; 2006 Sep 01; 98(5):641-3. PubMed ID: 16923452
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.